Adapting and Evolving in an Era of Biologic Growth
A bioanalytical perspective
The expanding market for biologics, which totaled $157 billion worldwide in 2011, is forecast by the IMS Institute to increase to $200-210 billion in 2016. Such products - including vaccines, blood and blood components, somatic cells, gene therapy, and recombinant therapeutic proteins - demand a corresponding evolution in bioanalytical technologies and practices to meet new scientific challenges and associated regulatory requirements.
Q2 Solutions offers complete bioanalytical and ADME solutions for testing around the globe and across the product development spectrum. Download this insight brief to learn how we continue to advance our customers' efforts and lead the way in this evolving science and regulatory environment.
Stephen Lowes. Ph.D., Senior Scientific Director, Bioanalysis and ADME Services
Complete the form below to access this insight brief